Literature DB >> 18494699

Yellow fever-associated viscerotropic disease in Barcelona, Spain.

Jose Muñoz1, Anna Vilella, Cristina Domingo, Josep Maria Nicolas, Fernando de Ory, Manuel Corachan, Antonio Tenorio, Joaquim Gascon.   

Abstract

Yellow fever vaccine is a live, attenuated viral preparation from the 17D virus strain. Since 1996, 34 cases of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) have been described. We report a new case of YEL-AVD. Given the potential risks associated with the vaccine, physicians should consider vaccination only for patients truly at risk for exposure to yellow fever, especially for primovaccination.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18494699     DOI： 10.1111/j.1708-8305.2008.00209.x

Source DB:  PubMed          Journal:  J Travel Med        ISSN： 1195-1982            Impact factor:   8.490


  8 in total

1.  A case of yellow fever vaccine-associated viscerotropic disease in Ecuador.

Authors:  Richard W Douce; Diana Freire; Betzabe Tello; Gavino A Vásquez
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

2.  Detection of yellow fever 17D genome in urine.

Authors:  Cristina Domingo; Sergio Yactayo; Edinam Agbenu; Maurice Demanou; Axel R Schulz; Katjana Daskalow; Matthias Niedrig
Journal:  J Clin Microbiol       Date:  2010-11-24       Impact factor: 5.948

3.  STATEMENT FOR TRAVELLERS AND YELLOW FEVER: An Advisory Committee Statement (ACS) Committee to Advise on Tropical Medicine and Travel (CATMAT).

Authors:  This Statement Was Prepared By P Charlebois
Journal:  Can Commun Dis Rep       Date:  2013-03-05

4.  Statement for Travellers and Yellow Fever: Committee to Advise on Tropical Medicine and Travel.

Authors:  P Charlebois
Journal:  Can Commun Dis Rep       Date:  2010-10-02

Review 5.  Yellow Fever Virus: Diagnostics for a Persistent Arboviral Threat.

Authors:  Jesse J Waggoner; Alejandra Rojas; Benjamin A Pinsky
Journal:  J Clin Microbiol       Date:  2018-09-25       Impact factor: 5.948

6.  Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination.

Authors:  Maria Luiza Silva; Luçandra Ramos Espírito-Santo; Marina Angela Martins; Denise Silveira-Lemos; Vanessa Peruhype-Magalhães; Ricardo Carvalho Caminha; Péricles de Andrade Maranhão-Filho; Maria Auxiliadora-Martins; Reinaldo de Menezes Martins; Ricardo Galler; Marcos da Silva Freire; Rugimar Marcovistz; Akira Homma; Dirk E Teuwen; Silvana Maria Elói-Santos; Mariléia Chaves Andrade; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho
Journal:  Clin Vaccine Immunol       Date:  2009-11-11

Review 7.  Yellow fever vaccine-associated viscerotropic disease: current perspectives.

Authors:  Roger E Thomas
Journal:  Drug Des Devel Ther       Date:  2016-10-12       Impact factor: 4.162

8.  Viscerotropic disease and acute uveitis following yellow fever vaccination: a case report.

Authors:  Lev Volkov; Gilda Grard; Pierre-Edouard Bollaert; Guillaume A Durand; Aurélie Cravoisy; Marie Conrad; Lionel Nace; Guilhem Courte; Rémy Marnai; Isabelle Leparc-Goffart; Sébastien Gibot
Journal:  BMC Infect Dis       Date:  2020-02-10       Impact factor: 3.090
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.